Top Section/Ad
Top Section/Ad
Most recent
A handful of large new listings have emerged from South Africa, Kenya and Angola and more are set to follow
Submarine mast maker's IPO raised €132.8m
Vincorion is expected to continue defence IPOs later this week
More articles/Ad
More articles/Ad
More articles
-
Ascletis Pharma is in the market with the first biotechnology IPO in Hong Kong following the bourse’s historic change in listing rules. -
Despite the outstanding performance of recent IPOs investors are still expecting to be wooed with significant discounts for new listings once the market kicks off again after the summer.
-
HDFC Asset Management is gunning for up to Rp28bn ($408m) from its IPO in India after setting the final price guidance for the offering.
-
Chinese firm Ascletis Pharma has launched bookbuilding for a HK$3.58bn ($456.9m) IPO, the first company to take advantage of the Hong Kong Stock Exchange’s new biotechnology-friendly listing regime.
-
The Hong Kong Stock Exchange and China’s two largest bourses have reached a consensus on when dual-class share companies can be included on the Stock Connect, following a surprise decision by the latter to exclude weighted voting rights (WVR) shares from the southbound channel of the cross-border trading system.
-
CanSino Biologics, founded by a group of Chinese vaccination industry experts from Canada, has filed for a listing in Hong Kong.
